KCM
MNTA

Kingdon Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Kingdon Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100,000
Closed -$1.17M – 224
2014
Q1 		$1.17M Buy
+100,000
New +$1.69M 0.06% 166

Other funds holding MNTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kingdon Capital Management's MNTA Position: Q3 2014 in Review

Kingdon Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2014, closing a stake of 150,000 shares — an estimated $1.81M sold.

Kingdon Capital Management first reported a position in MNTA in Q2 2014 and held it in 1 quarter. The position peaked at $1.81M in Q2 2014. 143 funds tracked by Wall St. Rank hold MNTA as of Q3 2014.

  • Kingdon Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Kingdon Capital Management sold 150,000 Momenta Pharmaceuticals, Inc. shares in Q3 2014, an estimated $1.81M.
  • Kingdon Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Kingdon Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $1.81M in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2014.

Based on Kingdon Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.